The VAD Journal: The journal of mechanical assisted circulation and heart failure

Peer-Reviewed Case Report

VeraFlo Negative Pressure Wound
Therapy with Household Bleach for
Refractory Driveline Infection in a
Patient with Left Ventricular Assist
Device
Amr Idris MD*, Amanda Hart, Sarah Branam, and Maya Guglin MD
Division of Cardiovascular Medicine, Linda and Jack Gill Heart Institute,
University of Kentucky, Lexington, KY 40503
* Corresponding author: amr.idris@uky.edu
Citation: Idris, A. et al. (2015).
"VeraFlo Negative Pressure
Wound Therapy with Household
Bleach for Refractory Driveline
Infection in a Patient with Left
Ventricular Assist Device," The
VAD Journal, 1. doi:
http://dx.doi.org/10.13023/VAD.2
015.10
Editor-in-Chief: Maya Guglin,
University of Kentucky
Received: July 15, 2015
Accepted: July 26, 2015
Published: July 27, 2015
© 2015 The Author(s). This is an
open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the
publication source are credited.

Abstract:
Driveline infections and sepsis are amongst the most common causes of
morbidity and mortality in a patient with a left ventricular assist device. In this
case, we present a patient with a multi drug resistant pseudomonas aeruginosa
driveline exit site infection. Initially, it was treated with dual antibiotics, followed
by surgical debridement utilizing Dakin’s solution irrigation and standard negative
pressure wound therapy. Wound healing was minimal determined by poor
granulation appearance, unchanged size from surgical debridement, purulent
drainage, and the wound base remained colonized with multi drug resistant
pseudomonas aeruginosa. A novel treatment of VeraFlo negative pressure
wound therapy in conjunction with indwelling Dakin’s solution into the wound
base was introduced. This treatment resulted in improved granulation
appearance, decreased drainage, decreasing in wound size, with positive
changes noticeable in 7 days. We suggest that the use of VeraFlo negative
pressure wound therapy may be used for treatment for cumbersome driveline
infections.
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Introduction:
Left ventricular assist device (LVAD) is indicated to provide mechanical
circulatory support for patients with advanced heart failure as a bridge to heart
transplantation or as a destination therapy. LVAD support has been linked to
increased survival and quality of life amongst this patient population (1-4). The
long term support with LVAD implant may be jeopardized by adverse events
such as driveline infection (5). The most common microorganisms leading to
driveline infections are biofilm forming organisms such as staphylococcus and
pseudomonas aeruginosa (6). Stabilization of the driveline can aid in preventing
exit site infections (7). Several treatments for driveline site infections have been
suggested including but not limited to topical and systemic antibiotics, pump
exchange, and new tunnel of the driveline exit site (6). Vacuum Assisted Closure
(VAC) VeraFlo Therapy (Kinetic Concepts, Inc, San Antonio, TX, USA) combines
negative pressure wound therapy with instillation of antimicrobial solution, which
cleanses the wound, treats the wound with antiseptic solution, and facilitates
healing of the wound. Instillation of the antimicrobial solution are programmed at
set intervals which aids in loosening contaminants followed by removal of
infectious material resulting in a lower bacterial burden (8, 9). In addition, VAC
VeraFlo Therapy has shown that it controls wound cleansing with less
aerosolisation compared with standard techniques. Therefore, it reduces the
potential spread of biofilm-producing microorganisms during wound cleansing
and environmental contamination associated with lavage (10).

Case Report:
A 62 year old woman with a history of a chemotherapy induced cardiomyopathy
received a HeartWare LVAD as destination therapy. In a year, she developed
pump thrombosis, and the LVAD was exchanged. The driveline exit site was
alternated from the right to the left lower quadrant of the abdomen.
Three months post implant of the new device, the patient accidentally dropped
the controller and pulled the driveline. Several days later, she developed left
lower quadrant pain, mild erythema, and increased mobility of the driveline
accompanied by drainage. The driveline culture was positive for pan-susceptible
pseudomonas. At the time of presentation, abdominal computer tomography (CT)
revealed a fluid collection around the proximal portion of the driveline with
inflammatory changes throughout the remainder of the driveline. Intravenous
cefepime and oral ciprofloxacin was given for four weeks. Driveline was
stabilized with two sutures.
Two weeks post completion of intravenous antibiotics, the patient came to the
emergency department with sepsis (fever, chills, tachycardia, fatigue, and
leukocytosis). Examination of the driveline exit site revealed left lower quadrant
tenderness, mild erythema, serosanguinous drainage, and complete
disincorporation of the driveline (Figure 1).
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Figure 1: Driveline exit site
The driveline exit site was re-cultured in which revealed Pseudomonas
susceptible to cefepime, which was started. Despite antibiotics, the abdominal
pain was worsening. Repeat CT scan revealed abscess involving the entire
length of the driveline. The patient was taken to the operating room for wound
debridement. Surgical removal of infected tissue, wash out with Dakin’s solution,
instillation of cefepime powder and pneumovac with continuous negative
pressure and standard black foam was placed. The wound measured abscess
was found to be more involved then what the CT scan results showed, with
wound measurements (17cm (length) x 7cm (width) x 5cm (depth)) incision was
made resulting in removal of the infected tissue, (Figure 2).
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Figure 2. Wound after surgical debridement; 17x7x5 cm
During wound vac, dressing changes completed only by a trained ventricular
assist devices Coordinator every 48 hours; velour of driveline was cleansed with
topical Dakin’s solution in addition to placing cefepime powder in wound bed.
Despite best efforts, no improvement of the wound bed occurred 26 days post
debridement (Figure 3). The wound had same size, with the bed covered with
purulent discharge.

Figure 3. Wound in 26 days after surgical debridement, on intravenous
antibiotics. Size 16x6x4 cm.
VeraFlo negative pressure wound therapy with infusion was initiated on day 26
post-debridement in which we utilized normal saline instillation into the wound
bed. The VeraFlo dressing was changed every 48 hours. The first VeraFlo
dressing change prompted the team to switch the saline instillation to Dakin’s
Infusion (65ml Infusion of Dakin’s solution with 10 minutes dwell time every 3.5
hours). Prior to the dressing change, the wound bed was re-cultured and
revealed a multi-drug resistant pseudomonas. Antibiotics were switched given
sensitivities now best treated with intravenous ciprofloxacin.
Within three days of changing to Dakin’s instillation, the wound showed signs of
improvement as evidenced by increased granulation, lack of purulent drainage,
improving size. VeraFlo therapy was utilized for a total of seven dressing
changes with 14 days of Dakin’s instillation. Patient was then able to be
transitioned back to the standard pneumovac. Patient was able to be discharged
home with home health nurse and pneumovac therapy in addition to Prisma AG
collagen product being placed in wound bed. When comparing the wound
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measurements from day 1 post debridement to day 34, initiation of VeraFlo
therapy with Dakin’s solution revealed the most improvement (Figure 4).

Figure 4 A. Day 6 on Dakin’s solution. Size 14.8 x5.8 x 4 cm

Figure 4 B. Day 10 on Dakin’s solution. Size 14 x5.8 x 3.8 cm
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Figure 4 C. Day 16 on Dakin’s solution. Size 14 x4.6 x 3.5 cm

Figure 4 D. Day 25 on Dakin’s solution. Size 14 x 4 x 3 cm
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Figure 4 E. Day 2 after discharge. Size 14 x 4 x 2.5 cm

Figure 4 F. Day 15 after discharge. Size 13 x 2.5 x 1.5 cm
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Figure 4G. Day 20 after discharge. Size 11 x 1.5x 1cm
Discussion
Until LVADs become fully implantable, the driveline infection will continue to be
one of the most common sources of morbidity and mortality in this patient
population (6).
Recurrent driveline trauma, tension on the wound edge, and localized hematoma
of the pump pocket have been factors in which predispose patients to bacterial
colonization and subsequent infection (11-14).
Dakin’s solution consists of diluted sodium hypochlorite; i.e. household bleach
which has broad antimicrobial activity (15). Dakin was first used as a topical
antiseptic during World War I (16). Currently, Dakin’s solution is available
commercially at full strength (0.5%), half strength (0.25%, quarter strength
(0.125%) and 1/40 strength (0.0125%)
Vacuum assisted closure has been used frequently in the context of negative
pressure wound therapy, which involves automated wound cleansing and
removal of infectious materials. VeraFlo negative pressure wound therapy
integrates standard pneumovac with infusion of solution at a timed and
intermittent delivery (17). Gabriel et al. reported “a significant decrease in the
meantime to bioburden reduction, wound closure, and hospital discharge” when
using negative pressure wound with infusion (18).
Previously, Raad et al. applied this therapy with Dakin’s instillation to five patients
with venous stasis ulcers greater than 200 cm2. Two of those patients had multi
drug resistant pseudomonas aeruginosa as the causative organism. All patients
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in this study had complete wound healing at one year (19). Our case is the first to
report the use of this therapy in patient with LVAD and driveline related infection.
In this case, multiple modalities were utilized including intravenous antibiotics
(cefepime and meropenum), oral antibiotic (cirprofloxacin), surgical debridement,
topical cefepime powder with standard negative pressure wound therapy, and
pneumovac therapy with saline instillation. All failed to improve the wound bed.
Utilization of Dakin’s solution showed to be effective in treating large multi drug
resistant pseudomonas aeruginosa infected wound as discussed earlier. Our
case supports the utilization of this therapy in LVAD-related infections.
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